Laurus Labs Limited (NSE:LAURUSLABS)
India
· Delayed Price · Currency is INR | Market Cap | 281.19B |
| Revenue (ttm) | 52.73B |
| Net Income (ttm) | 2.00B |
| Shares Out | 539.25M |
| EPS (ttm) | 3.70 |
| PE Ratio | 140.87 |
| Forward PE | 51.83 |
| Dividend | 0.80 (0.15%) |
| Ex-Dividend Date | Nov 6, 2024 |
| Volume | 3,104,432 |
| Average Volume | 4,011,010 |
| Open | 536.75 |
| Previous Close | 536.75 |
| Day's Range | 518.00 - 541.45 |
| 52-Week Range | 373.10 - 646.20 |
| Beta | 1.17 |
| RSI | 35.86 |
| Earnings Date | Apr 25, 2025 |
About Laurus Labs
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs. In addition, the company offers contract development and manufacturing organizational ser... [Read more]
Financial Performance
In 2023, Laurus Labs's revenue was 50.41 billion, a decrease of -16.55% compared to the previous year's 60.41 billion. Earnings were 1.61 billion, a decrease of -79.68%.
Financial StatementsNews
Stocks hitting 52-week high today, February 5: UPL, Laurus Labs, Bajaj Finance, JK Cement and more
On February 5, 2025, the Indian equity markets experienced a decline, with both the Nifty 50 and Sensex indices closing lower. Despite the market slowdown, several stocks managed to hit their 52-week ...
Laurus Labs stock jumps 5% after US grants emergency humanitarian waiver for HIV treatment
Laurus Labs’ stock price surged by 5% following the United States’ approval of an “emergency humanitarian waiver,” allowing continued access to HIV treatment across 55 countries. This waiver, crucial ...
Laurus Labs shares tumble amid concerns over US foreign aid pause impacting AIDS relief funding.
Hyderabad: The shares of Hyderabad-based pharma player Laurus Labs crashed 15% before recovering to close 11% down on the bourses on Monday.
Laurus Labs Ltd (BOM:540222) Q3 2025 Earnings Call Highlights: Strong CDMO Growth Amid ARV ...
Laurus Labs Ltd (BOM:540222) Q3 2025 Earnings Call Highlights: Strong CDMO Growth Amid ARV Challenges
Q3 2025 Laurus Labs Ltd Earnings Call Transcript
Q3 2025 Laurus Labs Ltd Earnings Call Transcript
Laurus Labs clarifies on reports of impact of Antiretroviral business, says no significant impact
Laurus Labs Limited has addressed recent media reports regarding the temporary freeze of funding under the US President’s Emergency Plan for AIDS Relief (PEPFAR) for 90 days. The company has clarified...
Laurus Labs shares fall 10% as ARV funding concerns weigh heavily
Shares of Laurus Labs fell sharply by 10% on January 27, 2025, closing at ₹542.40, amid negative sentiment triggered by reports of a potential halt in U.S. foreign aid funding for AIDS relief programs...
Laurus Labs Q3 FY25 Financial Results: Revenue up 18.4% YoY to Rs 1415.05 crore, Net Profit up 297% YoY
Laurus Labs Limited has released its consolidated unaudited financial results for the quarter ended December 31, 2024. The results highlight steady performance across revenue and profitability metrics...
Top stocks to watch in trade today: HUL, BPCL, Reliance Jio, Waaree Energies, Laurus Labs and more
Indian stock markets are expected to open on a subdued note, as indicated by GIFT Nifty futures. On Wednesday, the market saw a strong rally with the BSE Sensex surging 566 points or 0.75% to close at...
Stock Market Update, January 1: Muthoot Finance, Jubilant FoodWorks, Laurus Labs, Praj Industries and more hit 52-week highs today
The Indian equity markets closed on a positive note on January 1, 2025, with the Nifty crossing the significant 23,700 mark. The Sensex surged by 368.40 points, or 0.47%, closing at 78,507.41, while t...
Stock Market Update, December 31: Laurus Labs, Lupin, CRISIL and more hit 52-week highs today
As the Indian stock market closed its 2024 calendar year, investors witnessed notable gains. While the Sensex and Nifty 50 both recorded slight declines on the final day of the year, several stocks st...
Mixed trends in November CDRMO exports, prefer Syngene and Neuland Labs over Divis Labs and Laurus Labs
Goldman Sachs notes mixed trends in November for Indian contract development and manufacturing organizations (CDMOs). Monthly export figures showed variability, with Neuland Labs recording a sharp 276...
Laurus Bio secures 120 cr investment
Laurus Bio, a subsidiary of Laurus Labs, has received an equity investment of ₹120 crore from Eight Roads Ventures and F-Prime Capital, aimed at enhancing its fermentation-based manufacturing capabili...
T’gana pharma biggies to inject 5,200cr in Pharma City, create over 12,000 jobs
Top pharmaceutical companies in Telangana, including Laurus Labs and Gland Pharma, are set to invest ₹5,260 crore in the Pharma City project, aiming to create over 12,000 jobs while focusing on green ...
Pharma Sector Stocks: Granules down 1.68%, Akums slips 1.29%, Zydus Life up 0.13%, Aurobindo Pharma gains 0.99% in early trade
Time Stamp: November 4, 2024, 9:41 AM Market Update: Pharma stocks opened with a mixed trend today, showing slight gains and losses among the major players. SPARC: Down by 1.81%, trading at ₹212.04 PP...
Laurus Labs Ltd (BOM:540222) Q2 2025 Earnings Call Highlights: Navigating Challenges with ...
Laurus Labs Ltd (BOM:540222) Q2 2025 Earnings Call Highlights: Navigating Challenges with Strategic Growth Initiatives
Laurus Labs Q2 FY25 Results: Revenue flat, net profit declines 55% YoY
Laurus Labs has reported its Q2 FY25 financial results, showing a flat revenue performance while net profit dropped significantly year-on-year (YoY). Key Financial Highlights (YoY): Revenue: Q2 FY25: ...
Pharma stocks today: Gland Pharma rises 1.53%, Aurobindo Pharma up 1.38%, while Natco Pharma falls 1.40%, and Laurus Labs down 1.41%
As of 10:31 AM, the pharma sector has witnessed both gains and losses. Gland Pharma is the top gainer, rising by 1.53% to ₹1,675.40, followed by Aurobindo Pharma, up 1.38% at ₹1,493.00. Mankind Pharma...
Laurus Labs passes US FDA inspection for API manufacturing facility in Hyderabad
Laurus Labs Ltd has recently informed exchanges that the company successfully completed the US Food and Drug Administration (US FDA) audit of its API manufacturing plant in Hyderabad. The audit result...
Laurus Labs share jumps 5% after US House passes Biosecure Act
Laurus Labs’ stock rose more than 5% in early trading after the US House of Representatives passed the Biosecure Act, which aims to strengthen the pharmaceutical supply chain and promote domestic dome...